82 related articles for article (PubMed ID: 23350710)
1. Sulfated small molecules targeting eBV in Burkitt lymphoma: from in silico screening to the evidence of in vitro effect on viral episomal DNA.
Lima RT; Seca H; Palmeira A; Fernandes MX; Castro F; Correia-da-Silva M; Nascimento MS; Sousa E; Pinto M; Vasconcelos MH
Chem Biol Drug Des; 2013 May; 81(5):631-44. PubMed ID: 23350710
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
De Leo A; Arena G; Stecca C; Raciti M; Mattia E
Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
[TBL] [Abstract][Full Text] [Related]
3. Viral response to chemotherapy in endemic burkitt lymphoma.
Tang W; Harmon P; Gulley ML; Mwansambo C; Kazembe PN; Martinson F; Wokocha C; Kenney SC; Hoffman I; Sigel C; Maygarden S; Hoffman M; Shores C
Clin Cancer Res; 2010 Apr; 16(7):2055-64. PubMed ID: 20233888
[TBL] [Abstract][Full Text] [Related]
4. Aspirin induces lytic cytotoxicity in Epstein-Barr virus-positive cells.
Liu SF; Wang H; Li ZJ; Deng XY; Xiang H; Tao YG; Li W; Tang M; Cao Y
Eur J Pharmacol; 2008 Jul; 589(1-3):8-13. PubMed ID: 18571159
[TBL] [Abstract][Full Text] [Related]
5. Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents.
Ghosh SK; Forman LW; Akinsheye I; Perrine SP; Faller DV
Blood Cells Mol Dis; 2007; 38(1):57-65. PubMed ID: 17161633
[TBL] [Abstract][Full Text] [Related]
6. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.
Abdulkarim B; Sabri S; Zelenika D; Deutsch E; Frascogna V; Klijanienko J; Vainchenker W; Joab I; Bourhis J
Oncogene; 2003 Apr; 22(15):2260-71. PubMed ID: 12700662
[TBL] [Abstract][Full Text] [Related]
7. Damage induced in episomal EBV DNA in Raji cells by antitumor drugs as measured by pulsed field gel electrophoresis.
Johnson PG; Beerman TA
Anal Biochem; 1994 Jul; 220(1):103-14. PubMed ID: 7526729
[TBL] [Abstract][Full Text] [Related]
8. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
9. Zebularine reactivates silenced E-cadherin but unlike 5-Azacytidine does not induce switching from latent to lytic Epstein-Barr virus infection in Burkitt's lymphoma Akata cells.
Rao SP; Rechsteiner MP; Berger C; Sigrist JA; Nadal D; Bernasconi M
Mol Cancer; 2007 Jan; 6():3. PubMed ID: 17214905
[TBL] [Abstract][Full Text] [Related]
10. Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo.
Westphal EM; Mauser A; Swenson J; Davis MG; Talarico CL; Kenney SC
Cancer Res; 1999 Apr; 59(7):1485-91. PubMed ID: 10197618
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of Epstein-Barr virus-encoded latent membrane protein by human herpesvirus 6 superinfection of EBV-carrying Burkitt lymphoma cells.
Cuomo L; Trivedi P; de Grazia U; Calogero A; D'Onofrio M; Yang W; Frati L; Faggioni A; Rymo L; Ragona G
J Med Virol; 1998 Jul; 55(3):219-26. PubMed ID: 9624610
[TBL] [Abstract][Full Text] [Related]
12. Quantitative profiling of housekeeping and Epstein-Barr virus gene transcription in Burkitt lymphoma cell lines using an oligonucleotide microarray.
Bernasconi M; Berger C; Sigrist JA; Bonanomi A; Sobek J; Niggli FK; Nadal D
Virol J; 2006 Jun; 3():43. PubMed ID: 16756670
[TBL] [Abstract][Full Text] [Related]
13. Reactivation of Epstein-Barr virus from latency.
Amon W; Farrell PJ
Rev Med Virol; 2005; 15(3):149-56. PubMed ID: 15546128
[TBL] [Abstract][Full Text] [Related]
14. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.
Westphal EM; Blackstock W; Feng W; Israel B; Kenney SC
Cancer Res; 2000 Oct; 60(20):5781-8. PubMed ID: 11059774
[TBL] [Abstract][Full Text] [Related]
15. Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
Ladell K; Dorner M; Zauner L; Berger C; Zucol F; Bernasconi M; Niggli FK; Speck RF; Nadal D
Cell Microbiol; 2007 Aug; 9(8):2055-69. PubMed ID: 17419714
[TBL] [Abstract][Full Text] [Related]
16. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus integrates frequently into chromosome 4q, 2q, 1q and 7q of Burkitt's lymphoma cell line (Raji).
Gao J; Luo X; Tang K; Li X; Li G
J Virol Methods; 2006 Sep; 136(1-2):193-9. PubMed ID: 16806502
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency.
Hamilton-Dutoit SJ; Rea D; Raphael M; Sandvej K; Delecluse HJ; Gisselbrecht C; Marelle L; van Krieken HJ; Pallesen G
Am J Pathol; 1993 Oct; 143(4):1072-85. PubMed ID: 8214003
[TBL] [Abstract][Full Text] [Related]
19. Integration of Epstein-Barr virus into chromosome 6q15 of Burkitt lymphoma cell line (Raji) induces loss of BACH2 expression.
Takakuwa T; Luo WJ; Ham MF; Sakane-Ishikawa F; Wada N; Aozasa K
Am J Pathol; 2004 Mar; 164(3):967-74. PubMed ID: 14982850
[TBL] [Abstract][Full Text] [Related]
20. A molecular link between malaria and Epstein-Barr virus reactivation.
ChĂȘne A; Donati D; Guerreiro-Cacais AO; Levitsky V; Chen Q; Falk KI; Orem J; Kironde F; Wahlgren M; Bejarano MT
PLoS Pathog; 2007 Jun; 3(6):e80. PubMed ID: 17559303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]